WALTHAM, Mass., April 30 /PRNewswire/ -- According to Millennium Research Group's (MRG) US Markets for Gynecological Devices 2008 report, the female sterilization market was worth over $80 million in 2007. Driven by increasing demand for transcervical procedures, this market is expected to grow to almost $245 million by 2012.
Currently, Conceptus is the only player in the transcervical sterilization device market; however, MRG estimates Hologic to launch Adiana, its new female sterilization product, in 2009. Through 2012, growth in the number of doctors performing transcervical sterilization procedures, particularly those operating in an office setting, will fuel market expansion.
"In 2007, growth in the US female sterilization market came from the rapidly expanding transcervical sterilization device market, while both the mechanical and bipolar sterilization device markets declined from 2006," says Barbara Prud'homme, Senior Analyst at Millennium Research Group. "Over the next five years, this trend will continue as transcervical sterilization becomes the standard of care for female sterilization procedures in the US market."
Direct-to-consumer advertising by Conceptus, using TV, radio, online, and print media, will further raise awareness of transcervical sterilization procedures. As more potential patients become aware of transcervical sterilization, demand for the procedure will increase, boosting unit sales.
The US Markets for Gynecological Devices 2008 report provides coverage of all key industry competitors, including Hologic, Gynecare, Conceptus, Boston Scientific, Cooper Surgical, and American Medical Systems. Other regions covered in this global series include Europe (France, Germany, Italy, and the UK).
About Transcervical Female Sterilization
Transcervical female sterilization refers to sterilization methods that involve reaching the fallopian tubes through the vagina and uterus. Transcervical female sterilization provides women with a minimally invasive permanent sterilization option that does not involve external scarring or the use of drugs or hormones to prevent pregnancy. This procedure can be performed in a gynecologist's office, with the patient able to return home the same day and resume normal activities within a short period of time.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Millennium Research Group